Provid Pharmaceuticals

Name

Provid Pharmaceuticals

Legal name

Provid Pharmaceuticals Inc.

Website

https://provid.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Drug discovery services
• Autoimmune disease therapeutics
• Multiple sclerosis treatment
• MHC class II inhibitors
• Medicinal chemistry

Headquarters

HQ city

Monmouth Junction

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue biotech company developing PV-3212 for multiple sclerosis and other autoimmune diseases. Revenue will be generated through licensing agreements, co-development partnerships, or acquisition by pharmaceutical companies once drug candidates reach clinical stages.
2. Drug Discovery Services: Fee-for-service medicinal chemistry and drug discovery services provided to biotech/pharma companies and academic institutions. Services include lead optimization, process research, and scale-up synthesis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Provid Pharmaceuticals is a drug discovery company developing small molecule peptide mimetic drugs that target MHC class II molecules, primarily HLA-DRB1*15:01 (DR15), to inhibit antigen presentation to autoreactive T cells. Its lead candidate PV-3212 is a second-generation, picomolar-affinity inhibitor being advanced for multiple sclerosis and other DR15-associated autoimmune diseases. The company also provides contract medicinal chemistry and drug discovery services to biotech, pharma, and academic clients.

Product overview

Provid Pharmaceuticals is a biotechnology company developing a novel drug pipeline centered on MHC class II inhibition for autoimmune diseases. The core product is PV-3212, a second-generation small molecule DR15 inhibitor for multiple sclerosis, supported by first-generation lead PV-267. The pipeline extends to DR15 inhibitors for Goodpasture's disease and prodromal Parkinson's. The company also offers contract drug discovery services including medicinal chemistry, lead optimization, and process research across multiple therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• PV-3212 PV-3212 is a novel, second-generation small molecule drug candidate and potent inhibitor of the major histocompatibility class II molecule HLA-DRB1*15:01 (DR15) for the treatment of multiple sclerosis. It has picomolar binding affinity, high metabolic stability, and 20+ years of patent life. Being advanced by Provid for in-licensing or co-development with pharmaceutical partners.
• DR15 Inhibitor for Goodpasture's / Anti-GBM A DR15 inhibitor candidate targeting Goodpasture's disease (anti-glomerular basement membrane disease), a rare orphan autoimmune disease affecting the kidney and lung with incidence of 1-2 per million population. Pursued via Provid's MHC inhibition platform for a high-unmet-need indication lacking specific targeted treatments.
• DR15 Inhibitor for Prodromal Parkinson's Disease A DR15 inhibitor candidate targeting prodromal Parkinson's disease, where alpha-synuclein peptide antigen binds to DR15 triggering autoimmune pathology in the gut and enteric nervous system. Addresses an underlying autoimmune mechanism with no current targeted treatments.
• Drug Discovery Services US-based contract drug discovery services including expert medicinal chemistry, lead optimization, structure-based drug design, SAR, chemical process research, and translation to API. Delivered to biotech/pharma companies and academic institutions; licensed for DEA schedule IV research and SBIR/STTR eligible.

Quantifiable outcome

• 5X more potent in human cells compared to first generation PV-267
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Lawrence Steinman (Stanford University)coreStrategic or Co-development PartnerScientific Advisory Board member and clinical chair. Collaborating on clinical development strategy for PV-3212, including Phase Ib mechanistic proof-of-concept protocols.
• Thomas Forsthuber (UT San Antonio)coreStrategic or Co-development PartnerKey collaborator who demonstrated efficacy of PV-267 in DRB1*15:01 transgenic mice in EAE model of MS at UT San Antonio.
• Alessandro Sette (La Jolla Institute of Immunology)coreStrategic or Co-development PartnerCollaborator at La Jolla Institute of Immunology who evaluated PV-3212 and analogs for binding affinity to HLA-DRB1*15:01, DRB5:01:01, and DRB1*01:01.
• Joshua Ooi (Monash University)coreStrategic or Co-development PartnerCollaborator who evaluated PV-267 in DR15 transgenic mice model of Goodpasture's disease, demonstrating HLA-DR15 inhibition attenuates autoreactivity.
• SequenomminorOthersClient for drug discovery services - Isoform specific AKAP/PKA inhibitors
• Palatin TechnologiesminorOthersClient for drug discovery services for obesity drug candidate, which was licensed to AstraZeneca
• Arginetix/CorridorminorOthersClient for arginase inhibitor program, which was acquired by AstraZeneca
• Oncoceutics/ChimerixminorOthersClient for medchem discovery and process R&D collaboration on ONC201, ONC206, ONC212, and deuterated standards
• SupernusminorOthersClient for multiple prodrug programs in neurology and CNS

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Abata Therapeutics: Abata is developing autologous Treg cell therapies for progressive MS and other autoimmune diseases, with an antigen-specific, precision-medicine angle analogous to Provid's DR15-targeted approach. Both companies pursue selective immune modulation rather than broad immunosuppression.
• Cartesian Therapeutics: Cartesian is a clinical-stage cell therapy company developing RNA-engineered Treg and other immune-cell therapies for autoimmune and inflammatory diseases. Its antigen-specific immune-modulation approach makes it a relevant emerging peer to Provid's MHC-targeted strategy.
• Anokion SA: Anokion is a clinical-stage biotech engineering antigen-specific tolerance for autoimmune diseases, including MS and celiac disease. Its platform-based, immune-tolerance approach to autoimmune disease overlaps conceptually with Provid's MHC class II DR15 inhibition strategy.
• Clene Inc. Clene (NASDAQ: CLNN) is a clinical-stage biotech developing catalytically active nanotherapeutics for neurodegenerative diseases including MS and ALS. It is a comparable small-cap, neurology-focused biotech at a similar stage of development to Provid.
• Hookipa Pharma Inc. Hookipa (NASDAQ: HOOK) develops arenavirus-based immunotherapies for infectious disease and cancer, with an immunology platform rooted in antigen presentation and T cell activation — thematically aligned with Provid's MHC-driven mechanism of action.

Broad incumbents

• Biogen Inc. Biogen (NASDAQ: BIIB) is the historical MS market leader with franchises including Tysabri, Avonex, Plegridy, and Vumerity. Any new MS entrant such as Provid will need to compete against Biogen's established efficacy, safety, and prescriber base.
• TG Therapeutics: TG Therapeutics (NASDAQ: TGRX) markets ublituximab (Briumvi) for relapsing MS and has a broader MS and oncology franchise. It is a relevant broader incumbent competing in the same MS market that Provid's PV-3212 would eventually target.

Direct peers

• Apitope International NV: Apitope is developing antigen-specific immunotherapies for multiple sclerosis (ATX-MS-1467) and other autoimmune diseases. It is the most direct peer to Provid because both pursue peptide-based, antigen-presentation-targeted approaches in MS with the goal of inducing immune tolerance without broad immunosuppression.
• Immunic Therapeutics: Immunic (NASDAQ: IMUX) develops oral small-molecule therapies for MS (vidofludimus) and other chronic inflammatory and autoimmune diseases. It is a directly comparable MS-focused small-molecule biotech at a similar development stage to Provid's PV-3212 program.

Others

• Innate Pharma SA: Innate Pharma (NASDAQ: IPHA) is an immunology-focused biotech developing antibody-based therapies that modulate innate and adaptive immune responses. While its therapeutic modalities differ, its immunology R&D focus and comparable small-mid cap scale make it a relevant adjacent peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Provid Pharmaceuticals